Development of novel treatment strategy against Hodgkin lymphoma based on the immunopathogenesis

我们已经在体内NOG小鼠模型（携带人类肿瘤并植入人类免疫细胞）中证明了抗ccr4单抗可减少TIL中Treg细胞的数量。这些结果表明，使用抗ccr4单抗不仅可以治疗霍奇金淋巴瘤，还可以通过克服Treg细胞对宿主对肿瘤细胞免疫反应的抑制作用，为治疗许多其他类型的癌症提供一种新的策略。在不久的将来，抗ccr4单抗在后一种情况下的疗效也将在人体临床试验中得到证实。

We have demonstrated that the anti-CCR4 mAb reduces the number of Treg cells among TIL in an in vivo NOG mouse model (bearing human tumor & engrafted with human immune cells). These results indicate that use of anti-CCR4 mAb could represent a novel strategy for the treatment not only of Hodgkin lymphoma, but also many other types of cancer by overcoming suppressive effects of Treg cells on the host's immune response to tumor cells. In the near future, the efficacy of the anti-CCR4 mAb in the latter context will also be established in clinical trials in humans.